Traders work the floor of the New York Stock Exchange.

Check out which companies are making headlines before the bell:

Biogen's stock was under pressure ahead of the bell after the company's first-quarter sales of Tecfidera, an oral multiple sclerosis drug, came in at $824.90 million, below consensus estimates, according to Reuters.